In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide)
Analytical Biochemistry · 2025
DOI: 10.1016/j.ab.2025.115779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2025. Verfasst von Fadwa H Edrees und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nile Valley University (NVU), 63518, El Fayoum, Egypt. Hauptthemen laut MEDLINE: Thiazoles, Pyrazines, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nile Valley University (NVU), 63518, El Fayoum, Egypt.
- Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Alshaheed Shehata Ahmad Hegazy St, 62514, Beni-Suef, Egypt. Electronic address: maha.abdelrahman@pharm.bsu.edu.eg.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University (NUB), 62511, Beni-Suef, Egypt.
Zitieren
APA
Edrees, F. H., Abdelrahman, M. M., & Ahmed, A. B. (2025). In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide). Analytical Biochemistry. https://doi.org/10.1016/j.ab.2025.115779
Vancouver
Edrees FH, Abdelrahman MM, Ahmed AB. In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide). Analytical Biochemistry. 2025. doi:10.1016/j.ab.2025.115779
BibTeX
@article{Edrees2025,
author = {Edrees, Fadwa H and Abdelrahman, Maha M and Ahmed, Amal B},
title = {In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide)},
journal = {Analytical Biochemistry},
year = {2025},
doi = {10.1016/j.ab.2025.115779}
}
EUVIMED